CD44 and plasma cell myeloma: Additionally, using a fluorescent assay that was reported to sort putative CSC from lung cancer, breast cancer, and multiple myeloma [26], [27], [28] on the basis of differential ALDH activity, a small fraction of the MPE-derived primary tumors displayed the ALDHhi/CD44+ phenotype (Figure 6).